NCT02363855View on ClinicalTrials.gov

Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 23, 2015

Primary Completion Date

November 19, 2015

Study Completion Date

January 18, 2018

Conditions
Prostatic Neoplasms
Interventions
DRUG

BAY 1841788(ODM-201)

Cohort 1: Single dose 300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks Cohort 2: Single dose 2x300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks.

Trial Locations (1)

277-8577

Kashiwa

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY